Available from: Filippatos TD, Panagiotopoulou TV, Elisaf MS
Clinical trials consistently demonstrate that tirzepatide reduces both systolic and diastolic blood pressure by 2-8 mmHg through weight loss and improved insulin sensitivity
Importantly, liver transcriptomic analysis demonstrated that semaglutide reduced the expression of genes involved in hepatic steatosis, inflammation, and fibrosis, which was confirmed histologically for steatosis and inflammation, but not for fibrosis [33]
MAECENAS IACULIS Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui
There is no mention of compounded medications or disclosure of non-FDA approval, and you dont even know whats available until after your first appointment